Dr Paul Mulholland is a medical oncologist who exclusively treats brain cancer. He is a consultant at University College Hospital, the National Hospital for Neurology and Neurosurgery (part of UCLH) and Mount Vernon Cancer Centre, and he is chair of the HCA Cancer Care brain and CNS tumour board.
Dr Mulholland is also an honorary senior lecturer at University College London and a training programme director. He did his doctoral research in genomic profiling in brain cancer at the Cancer Research UK London Research Institute. This led to his focus on developing biomarkers and targets for therapy in brain cancer, including the clinical trial portfolio of novel agents in brain cancer which he now runs at UCLH and nationally.
Dr Mulholalnd's main research interests are understanding the immune microenvironment of glioblastoma and utilising this to improve the efficacy of immunotherapeutic agents in clinical practice.
Hi is also researching targeted hyperthermia (www.DARTRIX.eu) as a treatment modality for relapsed glioblastoma with Prof Kerry Chester at the UCL Cancer Institute.
Nicholas Brown, Thomas Carter, Paul Mulholland Dabrafenib in BRAFV600 mutated Anaplastic Pleomorphic Xanthoastrocytoma CNS Oncology. 2016. (in press)
Chiara Bardella, Osama Al-Dalahmah, Daniel Krell, Pijus Brazauskas, Khalid Al-Qahtani, Marketa Tomkova, Julie Adam, Sebastian Serres, Helen Lockstone, Inga Pfeffer, Nicola Sibson, Robert Goldin, Benjamin Schuster-Böeckler, Patrick Pollard, Tomoshi Soga, James McCullagh, Christopher Schofield, Paul Mulholland, Olaf Ansorge, Skirmantas Kriaucionis, Peter Ratcliffe, Francis G. Szele and Ian Tomlinson. Expression of the Idh1R132H driver mutation in the murine subventricular zone stem cell niche recapitulates early gliomagenesis. Cancer Cell. In Press, 2016
Thomas Carter, Paul Mulholland, Kerry Chester. Antibody-Targeted Nanoparticles for Cancer Treatment. Future Medicine. In Press, 2016.N F Brown, D Krell and P Mulholland. Chemotherapy for Brain Tumours. Book Chapter. Oxford Textbook of Neurosurgery. In Press, 2016.
Roy Rampling, Sharon Peoples, Paul J. Mulholland, Allan James, Omar Al-Salihi, Christopher J. Twelves, Catherine McBain, Sarah Jefferies, Alan Jackson, Willie Stewart, Juha Lindner, Sarah Kutscher, Norbert Hilf, Lesley McGuigan, Jane Peters, Karen Hill, Oliver Schoor, Harpreet Singh-Jasuja, Sarah E. Halford, James W.A. Ritchie. A Cancer Research UK First Time in Human Phase I Trial of IMA950 (Novel Multi-Peptide Therapeutic Vaccine) in Patients with Newly Diagnosed Glioblastoma. Clin Cancer Res. 2016 May 25. pii: clincanres.0506.2016.
Nicholas Brown, Catherine McBain, Stephen Nash, Kirsten I Hopkins, Paul Sanghera, Frank Saran, Mark Phillips, Fiona Dungey, Laura Clifton-Hadley, Katharina Wanek, Daniel Krell, Sarah Jeffries, Iftekhar Khan, Paul Smith, Paul Mulholland. Multi-center randomized phase II study comparing cediranib plus gefitinib with cediranib plus placebo in subjects with recurrent/progressive glioblastoma. PLoS One. 2016 May 27;11(5):e0156369. doi: 10.1371/journal.pone.0156369.
Thomas Carter, Heather Shaw, Denise Cohn-Brown, Kerry Chester, Paul Mulholland. Ipilimumab and bevacizumab in glioblastoma. Clin Oncol (R Coll Radiol). 2016 May 8. pii: S0936-6555(16)30076-0. doi: 10.1016/j.clon.2016.04.042. [Epub ahead of print]
Krell D, Mulholland P, Stebbing J, Tomlinson, Bardella C. Hot mutation screening in human glioblastoma. Future Science Open. 2015June doi:10.4155. Maha R.A. Abdollah, Tammy Kalber, Berend Tolner, Paul Southern, Joseph C. Beard, Mathew Robson, R. Barbara Pedley, Ivan P. Parkin, Quentin Pankhurst, Paul Mulholland and Kerry Chester. Prolonging the Circulatory Time of NIR-Dye Labelled SPION Using Dextran Sulfate. Faraday Discuss. 2014; 175:41-58.
Tracy Batchelor, Paul Mulholland, Bart Neyns, et al. Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J Clin Oncol. 2013 Sep 10;31(26):3212-3218.
Maclean J, Fersht N, Singhera M, Mulholland P et al. Multi-disciplinary management for patients with oligometastases to the brain: results of a 5 year cohort study. Radiat Oncol. 2013 Jun 27;8:156.
Daniel Krell, Paul Mulholland, Adam E. et al. Isocitrate Dehydrogenase mutations in tumourigenesis and their potential role as novel therapeutic targets. Future Oncology 2013 Dec;9(12):1923-35.
D Ulahannan, M B Kovac, P J Mulholland, J-B Cazier and I Tomlinson. Technical and implementation issues in using next-generation sequencing of cancers in clinical practice. Br J Cancer. 2013 Aug 20;109(4):827-35.
Tim Forshew, Paul Lewis, Adam Waldman, David Peterson, Mark Glaser, Cathryn Brock, Denise Sheer and Paul J. Mulholland. Three Different Brain Tumours Evolving from a Common Origin. Oncogenesis. 2013 Apr 1;2:e41.
Daniel Krell, Mauelikem Assoku, Malcolm Galloway, Paul Mulholland, Ian Tomlinson, Chiara Bardella. Screen for IDH1, IDH2, IDH3, D-2HGDH and L-2HGDH mutations in glioblastoma. PLoS One. 6 (5): e19868, 2011.
Paul J. Mulholland, Heike Fiegler, Patricia Gorman, Peter Sasieni, Joanna Adams, Koichi Ichimura, Jane W. Babbage, Tania A. Jones, Radost Vatcheva, Philip East, Philippa Carr, Chrysanthos Poullikas, V. Peter Collins, Nigel P. Carter, Ian P.M. Tomlinson & Denise Sheer. Genomic profiling identifies discrete deletions associated with translocations in glioblastoma multiforme. Cell cycle. 5(7): 783-791, 2006.
Mulholland PJ, Thirlwell C, Brock CS and Newlands ES. Emerging targeted treatments for astrocytic glioma. Expert opinion on emerging drugs. 10: 845-854, 2005.Paul J. Mulholland. Update on temozolomide in the management of glioblastoma multiforme. MIMS Adv. Neurooncology. 1(2): 14-15, 2005.
Paul J. Mulholland and Edward S. Newlands. Overview of the current medical management of primary brain tumours. MIMS Adv. Neurooncology. 1(1): 2-5, 2004.Mulholland PJ, Ferry DR, Anderson D, Hussain SA, Young AM, Cook JE, Hodgkin E, Seymore LW and Kerr DJ. Pre-clinical and clinical study of QC12, a water-soluble, pro-drug of quercetin. Ann Oncol. 12(2): 245-8, 2001.